indication

Schizophrenia, Treatment-Resistant

Competitive landscape projected to Bilateral M-ECT’s launch window

as of 2026-07-01
Competitive set
7
5 approved · 2 pipeline

Projection timeline

actual past → guided future · protection walls overlaid
45 events
2020
2024
2028
2032
2036
2040
today
Bilateral M-ECT launch window
guided / estimated ↑
actual ↓
focal / guidedapprovallabel expansiontrial readoutcongressnclustered events (click to expand)guided (dashed = directional)competitor patent cliff

Competitive set

resolved drugs with trials in this indication
drugCompleted
Clozapine
US-approved 1989 · Clozaril
Phase 44 trials
OwnerShanghai Mental Health Center
Protection2028
drugRecruiting
Aripiprazole
US-approved 2002 · ABILIFY
Phase 43 trials
OwnerOtsuka Pharmaceutical Development & Commercialization, Inc.
Protection2041
drugTerminated
Risperidone
US-approved 1993 · RISPERDAL
Phase 31 trial
OwnerJanssen, L.P. - Investigator Initiated Studies Program
Protection2042
drugTerminated
Olanzapine
US-approved 1996 · ZYPREXA Intramuscular
Phase 31 trial
OwnerEli Lilly and Company
Protection2041
drugUnknown
Paliperidone
US-approved 2006 · Erzofri extended-release
Phase 41 trial
OwnerJohnson & Johnson
Protection2041
drugCompleted
Amisulpride
Pipeline · Phase 4
Phase 42 trials
OwnerShanghai Mental Health Center
Protection2038
drugRecruiting
Evenamide
Pipeline · Phase 3
Phase 31 trial
OwnerNewron Pharmaceuticals SPA
Protection—

Market size

prevalence as a range, not a number